220,431 Shares in Azenta, Inc. $AZTA Bought by Meros Investment Management LP

Meros Investment Management LP bought a new stake in Azenta, Inc. (NASDAQ:AZTA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 220,431 shares of the company’s stock, valued at approximately $5,625,399. Azenta accounts for approximately 0.0% of Meros Investment Management LP’s portfolio, making the stock its 24th biggest position. Meros Investment Management LP owned approximately 0.50% of Azenta at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of AZTA. Caitong International Asset Management Co. Ltd grew its position in Azenta by 2,067.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after buying an additional 765 shares during the period. Assetmark Inc. boosted its holdings in shares of Azenta by 54.1% during the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares during the last quarter. State of Wyoming acquired a new position in shares of Azenta during the first quarter worth $38,000. Osaic Holdings Inc. raised its position in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares during the period. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Azenta by 98.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after purchasing an additional 689 shares during the last quarter. 99.08% of the stock is owned by institutional investors.

Azenta Trading Down 2.2%

Shares of NASDAQ AZTA traded down $0.74 during trading hours on Friday, reaching $32.87. The stock had a trading volume of 479,037 shares, compared to its average volume of 911,154. Azenta, Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $41.73. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -11.91 and a beta of 1.37. The firm has a 50-day moving average of $28.74 and a 200-day moving average of $25.14.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.The firm had revenue of $161.18 million during the quarter, compared to analyst estimates of $149.31 million.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on AZTA shares. Needham & Company LLC raised their price target on Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Azenta currently has a consensus rating of “Hold” and an average target price of $41.20.

About Azenta

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.